CymaBay Therapeutics Inc.

4.13-0.0700-1.67%Vol 302.25K1Y Perf -6.04%
Jul 23rd, 2021 16:00 DELAYED
BID4.12 ASK4.13
Open4.19 Previous Close4.20
Pre-Market- After-Market4.13
 - -  - -%
Target Price
11.40 
Analyst Rating
Strong Buy 1.10
Potential %
176.03 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★ —    -
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
★★★ —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap284.95M 
Earnings Rating
Sell
Price Range Ratio 52W %
12.59 
Earnings Date
9th Aug 2021

Today's Price Range

4.104.20

52W Range

3.429.06

5 Year PE Ratio Range

-7.90-2.90

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
0.24%
1 Month
-10.22%
3 Months
-6.98%
6 Months
-29.76%
1 Year
-6.04%
3 Years
-64.61%
5 Years
142.94%
10 Years
-

TickerPriceChg.Chg.%
CBAY4.13-0.0700-1.67
AAPL148.561.76001.20
GOOG2 756.3289.75003.37
MSFT289.673.53001.23
XOM57.04-0.0700-0.12
WFC44.59-0.4400-0.98
JNJ171.791.81001.06
FB369.7918.60005.30
GE12.710.01000.08
JPM150.64-0.2900-0.19
Earnings HistoryEstimateReportedSurprise %
Q01 2021-0.24-0.25-4.17
Q04 2020-0.20-0.23-15.00
Q03 2020-0.17-0.170.00
Q02 2020-0.23-0.1630.43
Q01 2020-0.31-0.1938.71
Q04 2019-0.39-0.3510.26
Q03 2019-0.37-0.38-2.70
Q02 2019-0.37-0.355.41
Earnings Per EndEstimateRevision %Trend
6/2021 QR-0.27-3.85Negative
9/2021 QR-0.30-3.45Negative
12/2021 FY-1.12-4.67Negative
12/2022 FY-1.11-5.71Negative
Next Report Date9th Aug 2021
Estimated EPS Next Report-0.27
Estimates Count8
EPS Growth Next 5 Years %-
Volume Overview
Volume302.25K
Shares Outstanding69.00M
Trades Count3.26K
Dollar Volume7.77M
Avg. Volume942.97K
Avg. Weekly Volume451.07K
Avg. Monthly Volume595.14K
Avg. Quarterly Volume748.49K

CymaBay Therapeutics Inc. (NASDAQ: CBAY) stock closed at 4.13 per share at the end of the most recent trading day (a -1.67% change compared to the prior day closing price) with a volume of 302.26K shares and market capitalization of 284.95M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 24 people. CymaBay Therapeutics Inc. CEO is Sujal Shah.

The one-year performance of CymaBay Therapeutics Inc. stock is -6.04%, while year-to-date (YTD) performance is -28.05%. CBAY stock has a five-year performance of 142.94%. Its 52-week range is between 3.42 and 9.06, which gives CBAY stock a 52-week price range ratio of 12.59%

CymaBay Therapeutics Inc. currently has a PE ratio of -5.10, a price-to-book (PB) ratio of 2.23, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -32.88%, a ROC of -36.75% and a ROE of -35.33%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from CymaBay Therapeutics Inc., there were 1 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.27 for the next earnings report. CymaBay Therapeutics Inc.’s next earnings report date is 09th Aug 2021.

The consensus rating of Wall Street analysts for CymaBay Therapeutics Inc. is Strong Buy (1.1), with a target price of $11.4, which is +176.03% compared to the current price. The earnings rating for CymaBay Therapeutics Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

CymaBay Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

CymaBay Therapeutics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 16.18, ATR14 : 0.20, CCI20 : -104.85, Chaikin Money Flow : 0.03, MACD : -0.08, Money Flow Index : 48.30, ROC : -2.13, RSI : 40.80, STOCH (14,3) : 39.13, STOCH RSI : 0.28, UO : 59.21, Williams %R : -60.87), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of CymaBay Therapeutics Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
9 (90.00 %)
8 (80.00 %)
3 (33.33 %)
Moderate Buy
1 (10.00 %)
1 (10.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
1 (10.00 %)
6 (66.67 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.10
Strong Buy
1.30
Moderate Buy
2.33

CymaBay Therapeutics Inc.

CymaBay Therapeutics Inc is a part of the healthcare sector based in the United States. Its main business involves the development of therapeutics such as Arhalofenate, MBX-8025, and MBX-2982. These drugs are intended to treat serious metabolic disorders. Arhalofenate is used to treat gout, MBX-2982 is an oral, G-protein coupled receptor agonist being evaluated as a therapeutic agent for patients with Type 2 diabetes and MBX-8025 is a selective agonist for the peroxisome proliferator-activated receptor delta.

CEO: Sujal Shah

Telephone: +1 510 293-8800

Address: 7575 Gateway Boulevard, Newark 94560, CA, US

Number of employees: 24

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

54%46%

Bearish Bullish

54%46%

News

Stocktwits